Eli Lilly To Invest Over USD1 Bn In Contract Manufacturing Expansion In India, Sets Up New Hub In Hyderabad

Global pharmaceutical giant Eli Lilly and Company today announced its mega plans to invest more than USD1 billion over the coming years to expand its contract manufacturing capabilities in India. This strategic investment aims to strengthen the company’s manufacturing and supply chain to support its growing portfolio of innovative medicines and enhance patients’ access worldwide.

As part of the expansion, Lilly will establish a new manufacturing and quality hub in Hyderabad. The facility will provide advanced technical capabilities and oversight for Lilly’s contract manufacturing network across India. Recruitment for various roles including engineers, chemists, analytical scientists, quality control and assurance professionals, and management positions will begin immediately, said a statement here.

This initiative reflects Lilly’s intent to leverage India’s highly skilled talent pool to support its global manufacturing growth and deliver life-saving medicines to patients across the globe. Since 2020, Eli Lilly has committed over USD55 billion to build, expand, and acquire manufacturing facilities in the United States and internationally. These investments address growth in medicines for diabetes, obesity, Alzheimer’s disease, cancer, autoimmune conditions, and prepare for future therapies.

Revanth Reddy, Chief Minister of Telangana, lauded Lilly’s expanding footprint in Hyderabad, calling it a testament to the city’s emergence as a global healthcare innovation hub. “Lilly’s new manufacturing and quality hub, along with its innovation and technology sites, reinforce Telangana’s position as a preferred destination for cutting-edge healthcare investments,” he said.

Sridhar Babu, Minister for IT, Electronics & Communications, Industries & Commerce, and Legislative Affairs, Telangana, emphasized the state’s dynamic industrial environment. “Lilly’s growth in Hyderabad highlights Telangana’s technology-driven infrastructure and its increasing prominence in advanced healthcare manufacturing,” he added.

Nivruti Rai, Managing Director & CEO of Invest India, Union Ministry of Commerce & Industry, praised the investment as a reflection of India’s emergence as a global manufacturing and innovation hub. “Lilly’s commitment underscores confidence in India’s skilled workforce, robust infrastructure, and business-friendly policies,” she said, expressing support for the company’s growth journey in the country.

Patrik Jonsson, Executive Vice President and President of Lilly International, said, “We are making significant investments to increase manufacturing and medicine supply capacity worldwide to ensure patients have access to the medicines they need. Partnering with trusted contract manufacturers expands our ability to deliver life-changing medicines at scale with quality at the core. This investment reaffirms our confidence in India as a key hub within our global network.”